FindTrial
Sign In

A study to explore clinical characteristics of the patients with lung cancer who were administered with tyrosine kinase inhibitors

A multi-centre real-world observational study to explore the patients with non-small cell lung cancer who were administered with tyrosine kinase inhibitors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014705
Enrollment
Unknown
Registered
2018-01-30
Start date
2018-02-01
Completion date
Unknown
Last updated
2018-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Case series:TKIs therapy

Sponsors

Tangdu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All the patients who met all of the following criteria will be included in the study: 1. Patients who were enrolled in clinics from 2013 to 2017; 2. Patients with clinical staging IV non-small cell lung cancer; 3. Diagnosed patients with lung cancer complicated with brain metastases; 4. Patients with clinical effectiveness data as per requested by RECIST 1.1; 5. Patients with tyrosine kinase inhibitors (TKIs) only or combination of TKIs and other cancer treatments.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Object Remission Rate;—

Secondary

MeasureTime frame
Progress-free survival;—

Countries

China

Contacts

Public ContactHelong Zhang

Tangdu Hospital

cnxazhl@163.com+86 029 84777777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026